Life Sciences

LiMM Therapeutics incorporated to translate breakthrough science into first in class therapeutic agents
25 June 2019

LiMM Therapeutics incorporated to translate breakthrough science into first in class therapeutic agents

LiMM Therapeutics was created to lead development of a new class of therapeutic agents - neuronal reprogrammers of innate lymphocytes. The company is based on pioneering...

Read the press release
Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
13 May 2019

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

Read more
Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings
8 May 2019

Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings

Upheld patent EP2575835 covers therapeutic compositions of clostridial bacterial species derived from the human microbiome. Decision further solidifies Vedanta’s leading IP...

Read more
Enterome announces research collaboration with renowned US Cancer Institute focused on new microbiome-derived cancer immunotherapy
22 March 2019

Enterome announces research collaboration with renowned US Cancer Institute focused on new microbiome-derived cancer immunotherapy

New collaboration to evaluate the potential of bacterial antigens that mimic tumor antigens and neoantigens ("onco-mimics") to drive immune responses.

Read the press release
BiomX raises $32M series B to bring first two therapies to clinic
21 February 2019

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday, 20th February, that will take its lead candidate, acne therapy BX001,...

Read more
Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800
19 February 2019

Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800

Vedanta Bioscience, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

Read more

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse